Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESC-HBR trial
2023-000029-10Phase 3Active
- Sponsor
- Azienda Ospedaliera Universitaria Gaetano Martino
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prasugrel, ticagrelor, clopidogrel and aspirin in acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Azienda Ospedaliera Universitaria Gaetano Martino. Primary endpoint: Optimal platelet reactivity at steady state. Started Jan 2023; status: active.
02
Drugs
prasugrelticagrelorclopidogrelaspirin
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2023-000029-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000029-10.